Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-28Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; currently active-not-recruiting.
-
CLINICAL_TRIALS trial_result · 2026-07-31Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial exploring pembrolizumab as adjuvant therapy for triple-negative breast cancer is actively not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating pembrolizumab as adjuvant therapy for triple-negative breast cancer is active/not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours [Phase 1, Phase 2]
Phase 1/2 trial results of NUC-3373 in combination with other agents in patients with advanced solid tumors; study status terminated with re…
-
CLINICAL_TRIALS trial_result · 2026-07-21Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 clinical trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; status ACTIVE_NOT_RECRUITIN…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Results: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer [EARLY_Phase 1]
Early-phase trial results of adjuvant alpha-lactalbumin vaccine in triple-negative breast cancer were completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2026-07-13Clinical Trial Results: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]
Phase 1/2 trial results for TC-510 in advanced mesothelin-expressing cancers were terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2026-07-07Clinical Trial Results: Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations [Phase 2]
Phase 2 trial evaluating nab-paclitaxel in combination with alpelisib for anthracycline-refractory triple-negative breast cancer with PIK3CA…
-
CLINICAL_TRIALS trial_result · 2026-07-02Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 clinical trial update for pembrolizumab as adjuvant therapy in triple-negative breast cancer, status ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2026-07-01Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer is ongoing with active status.
-
CLINICAL_TRIALS trial_result · 2026-06-17Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial updating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; study status ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial investigating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; currently active but not recruiti…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
This is an update on a Phase 3 trial evaluating pembrolizumab (Keytruda) as adjuvant therapy for triple-negative breast cancer, with the stu…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers [Phase 1]
A Phase I trial evaluating [177Lu]Lu-NNS309, a radiopharmaceutical, in multiple advanced cancers including pancreatic ductal adenocarcinoma,…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
A real-world, patient-reported outcome study of Sacituzumab Govitecan in Chinese patients with metastatic triple-negative breast cancer; the…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating the combination of tamoxifen and pegylated liposomal doxorubicin for metastatic or locally advanced trip…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating atezolizumab plus capecitabine as adjuvant therapy for triple-negative breast cancer, reporting on efficacy and saf…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial of GTAEXS617 in adults with advanced solid tumors is currently recruiting. The study encompasses head and neck sq…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
AstraZeneca is conducting a Phase 1/2 trial to evaluate the safety of AZD6750 in adults with select advanced or metastatic solid tumors; the…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer [Phase 3]
A Phase 3 trial is evaluating camrelizumab in combination with apatinib and eribulin versus physician's choice chemotherapy in metastatic tr…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) [Phase 3]
Phase 3 trial NCT06393374 evaluates Sacituzumab govitecan with pembrolizumab versus treatment of physician's choice in triple-negative breas…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells [Phase 1]
Phase 1 study of autologous CAR-T cells targeting B7-H3 (iC9-CAR.B7-H3 T Cells) for triple-negative breast cancer; the trial is currently re…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer [Phase 3]
A Phase 3 trial of sacituzumab govitecan in primary HER2-negative breast cancer (including triple-negative breast cancer) is currently activ…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors [Phase 1]
BeiGene is conducting a Phase 1 safety study to evaluate different doses of BG-68501 in participants with various advanced-stage cancers, an…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease [Phase 2]
Clinical trial update for PREDICT-RD, a Phase 2 study assessing ctDNA surveillance in patients with residual disease in triple-negative brea…